Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells

Labsch,Sabrina; Liu,Li; Bauer,Nathalie; Zhang,Yiyao; Aleksandrowicz,Ewa; Gladkich,Jury; Schönsiegel,Frank; Herr,Ingrid

doi:10.3892/ijo.2014.2335

Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells

Authors:
- Sabrina Labsch
- Li Liu
- Nathalie Bauer
- Yiyao Zhang
- Ewa Aleksandrowicz
- Jury Gladkich
- Frank Schönsiegel
- Ingrid Herr
View Affiliations

Affiliations: Experimental Surgery, General, Visceral and Transplantation Surgery, University of Heidelberg, D-69120 Heidelberg, Germany
Published online on: March 10, 2014 https://doi.org/10.3892/ijo.2014.2335
Pages: 1470-1480
Copyright: © Labsch et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced androgen-independent prostate cancer (AIPC) is an aggressive malignancy with a poor prognosis. Apoptosis-resistant cancer stem cells (CSCs) have been identified in AIPC and are not eliminated by current therapeutics. Novel therapeutic options, which are currently being evaluated in patient studies, include TRAIL and the broccoli-derived isothiocyanate sulforaphane. Although neither agent targets normal cells, TRAIL induces apoptosis in most cancer cells, and sulforaphane eliminates CSCs. In this study, the established AIPC cell lines DU145 and PC3, with enriched CSC features, and primary patient-derived prostate CSCs were treated with sulforaphane and recombinant soluble TRAIL. We examined the effects of these drugs on NF-κB activity, self-renewal and differentiation potential, and stem cell signaling via spheroid- and colony-forming assays, FACS and western blot analyses, immunohistochemistry, and an antibody protein array in vitro and after xenotransplantation. We largely found a stronger effect of sulforaphane on CSC properties compared to TRAIL, though the agents acted synergistically when applied in combination. This was associated with the inhibition of TRAIL-induced NF-κB binding; CXCR4, Jagged1, Notch 1, SOX 2, and Nanog expression; ALDH1 activity inhibition; and the elimination of differentiation and self-renewal potential. In vivo, tumor engraftment and tumor growth were strongly inhibited, without the induction of liver necrosis or other obvious side effects. These findings suggest that sulforaphane shifts the balance from TRAIL-induced survival signals to apoptosis and thus explains the observed synergistic effect. A nutritional strategy for high sulforaphane intake may target the cancer-specific activity of TRAIL in CSCs.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2.	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Sharpe B, Beresford M, Bowen R, Mitchard J and Chalmers AD: Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev. 9:721–730. 2013. View Article : Google Scholar : PubMed/NCBI
4.	Abbott A: Cancer: the root of the problem. Nature. 442:742–743. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Stuckey DW and Shah K: TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 19:685–694. 2013. View Article : Google Scholar : PubMed/NCBI
6.	Szegezdi E, O’Reilly A, Davy Y, et al: Stem cells are resistant to TRAIL receptor-mediated apoptosis. J Cell Mol Med. 13:4409–4414. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Herr I and Büchler MW: Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer. Cancer Treat Rev. 36:377–383. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Shankar S, Ganapathy S and Srivastava RK: Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 14:6855–6866. 2008. View Article : Google Scholar
9.	Kallifatidis G, Rausch V, Baumann B, et al: Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced anti-apoptotic signalling. Gut. 58:949–963. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Herr I, Lozanovski V, Houben P, Schemmer P and Buchler MW: Sulforaphane and related mustard oils in focus of cancer prevention and therapy. Wien Med Wochenschr. 163:80–88. 2013. View Article : Google Scholar : PubMed/NCBI
11.	Liu L, Salnikov AV, Bauer N, et al: Triptolide reverses hypoxia-induced EMT and stem-like features in pancreatic cancer by NF-kappa B downregulation. Int J Cancer. (In press).
12.	Apel A, Herr I, Schwarz H, Rodemann HP and Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 68:1485–1494. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Balke M, Neumann A, Szuhai K, et al: A short-term in vivo model for giant cell tumor of bone. BMC Cancer. 11:2412011. View Article : Google Scholar : PubMed/NCBI
14.	van Bokhoven A, Varella-Garcia M, Korch C, et al: Molecular characterization of human prostate carcinoma cell lines. Prostate. 57:205–225. 2003.PubMed/NCBI
15.	Pfeiffer MJ and Schalken JA: Stem cell characteristics in prostate cancer cell lines. Eur Urol. 57:246–255. 2010. View Article : Google Scholar : PubMed/NCBI
16.	van den Hoogen C, van der Horst G, Cheung H, et al: High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 70:5163–5173. 2010.
17.	Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB and Farrar WL: CD44⁺CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 98:756–765. 2008.
18.	Li H, Chen X, Calhoun-Davis T, Claypool K and Tang DG: PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 68:1820–1825. 2008. View Article : Google Scholar
19.	Patrawala L, Calhoun T, Schneider-Broussard R, et al: Highly purified CD44⁺ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 25:1696–1708. 2006.
20.	Glinsky GV: ‘Stemness’ genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 26:2846–2853. 2008.
21.	Luk SU, Yap WN, Chiu YT, et al: Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int J Cancer. 128:2182–2191. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Patrawala L, Calhoun-Davis T, Schneider-Broussard R and Tang DG: Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44⁺alpha2beta1⁺cell population is enriched in tumor-initiating cells. Cancer Res. 67:6796–6805. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Klarmann GJ, Hurt EM, Mathews LA, et al: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 26:433–446. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI and Gupta S: Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 121:1424–1432. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Zhao Y, Yan Q, Long X, Chen X and Wang Y: Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct. 26:571–577. 2008. View Article : Google Scholar : PubMed/NCBI
26.	Tomasi TB Jr: Structure and function of alpha-fetoprotein. Annu Rev Med. 28:453–465. 1977. View Article : Google Scholar : PubMed/NCBI
27.	Niwa H, Miyazaki J and Smith AG: Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 24:372–376. 2000. View Article : Google Scholar : PubMed/NCBI
28.	Mitsui K, Tokuzawa Y, Itoh H, et al: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 113:631–642. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Niwa H, Ogawa K, Shimosato D and Adachi K: A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 460:118–122. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Hazan RB, Qiao R, Keren R, Badano I and Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci. 1014:155–163. 2004. View Article : Google Scholar
31.	Akiyama Y, Watkins N, Suzuki H, et al: GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol. 23:8429–8439. 2003. View Article : Google Scholar
32.	Liu M, Lee DF, Chen CT, et al: IKKalpha activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell. 45:171–184. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Song Y, Washington MK and Crawford HC: Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010. View Article : Google Scholar
34.	Zhou Q, Brown J, Kanarek A, Rajagopal J and Melton DA: In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature. 455:627–632. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Niakan KK, Ji H, Maehr R, et al: Sox17 promotes differentiation in mouse embryonic stem cells by directly regulating extraembryonic gene expression and indirectly antagonizing self-renewal. Genes Dev. 24:312–326. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Bai RY, Staedtke V, Lidov HG, Eberhart CG and Riggins GJ: OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res. 72:5988–6001. 2012. View Article : Google Scholar : PubMed/NCBI
37.	Flores ER and Lozano G: The p53 family grows old. Genes Dev. 26:1997–2000. 2012. View Article : Google Scholar : PubMed/NCBI
38.	Kalisz M, Winzi M, Bisgaard HC and Serup P: EVEN-SKIPPED HOMEOBOX 1 controls human ES cell differentiation by directly repressing GOOSECOID expression. Dev Biol. 362:94–103. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Davidson NE and Sukumar S: Of Snail, mice, and women. Cancer Cell. 8:173–174. 2005. View Article : Google Scholar : PubMed/NCBI
40.	Holmes DI and Zachary IC: Vascular endothelial growth factor regulates stanniocalcin-1 expression via neuropilin-1-dependent regulation of KDR and synergism with fibroblast growth factor-2. Cell Signal. 20:569–579. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Triozzi PL and Stevens VC: Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep. 6:7–17. 1999.
42.	Gassmann P, Haier J, Schluter K, et al: CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 11:651–661. 2009.PubMed/NCBI
43.	Leong KG and Gao WQ: The Notch pathway in prostate development and cancer. Differentiation. 76:699–716. 2008. View Article : Google Scholar
44.	Douville J, Beaulieu R and Balicki D: ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 18:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
45.	Ding L, Yuan C, Wei F, et al: Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest. 29:511–520. 2011. View Article : Google Scholar
46.	Rajasekhar VK, Studer L, Gerald W, Socci ND and Scher HI: Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun. 2:1622011. View Article : Google Scholar : PubMed/NCBI
47.	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
48.	Kirsh VA, Peters U, Mayne ST, et al: Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst. 99:1200–1209. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Richman EL, Carroll PR and Chan JM: Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 131:201–210. 2012. View Article : Google Scholar : PubMed/NCBI